French pharma company Servier has acquired cancer drug Pixuvri (pixantrone) from US-based CTI BioPharma for an undisclosed price in a move to strengthen its oncology portfolio.
02 Oct 2019
01 Oct 2019
Celltrion announced that it is launching Temixy in the US, which were approved in November by US Food and Drug Administration (FDA).
27 Aug 2019
US-based Amgen has agreed to acquire Celgene’s psoriasis drug Otezla (apremilast) and certain related assets and liabilities for $13.4bn (£10.9bn) in cash.
22 Aug 2019
Pfizer is set to invest an additional $500m (£411m) to build an advanced gene therapy manufacturing facility in Sanford, North Carolina, US.
21 Aug 2019
German pharma giant Bayer has agreed to offload its animal health unit to Elanco Animal Health for $7.6bn (£6.27bn) in a stock-cum-cash deal, in a move to focus on its life sciences business.
07 Aug 2019
Gilead Sciences Canada announced that effective July 31, the Ontario Drug Benefit Program will provide eligible patients with access to Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) tablets, a once-daily single tablet and complete regimen for the treatment of HIV-1 infection in adults. Health Canada granted a Notice of Compliance for BIKTARVY in July 2018.
02 Aug 2019
Alvogen announced that its subsidiary Lotus Pharmaceuticals has launched Vinorelbine 20, 30 and 80mg soft capsules in Europe.
01 Aug 2019
Pfizer announced the closing of its joint venture (JV) with GlaxoSmithKline to combine the parties’ respective consumer healthcare businesses to create the world’s largest over-the-counter (OTC) business with robust iconic brands.
30 Jul 2019
Pfizer has agreed to merge its off-patent branded and generic established medicines business Upjohn with Mylan to establish a new global pharmaceutical company.
29 Jul 2019
Alvotech and Cipla Gulf enter into a partnership for the commercialization of key biosimilar in select emerging markets
Biopharmaceutical company Alvotech and Cipla Gulf FZ LLC ("Cipla Gulf"), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited announced that Alvotech and Cipla Gulf have entered into an exclusive partnership for the commercialization of AVT02, an adalimumab biosimilar, in select emerging markets.